Weekly injections remain foundational, but daily oral therapy adds another entry point into care, particularly for patients hesitant about needles or seeking a treatment that fits more seamlessly into a morning routine
To help, Equinox has launched a one-of-a-kind, research-backed GLP-1 protocol
NCT04255433) [23], comparing tirzepatide and dulaglutide, will provide insights into whether achieving more therapeutic goals with tirzepatide translates into a lower risk of major cardiovascular events
It focuses on treating the root causes of obesity and weight gain, such as hormonal imbalances, metabolism issues, or lifestyle factors
For more detailed guidance on injection site selection and rotation, see our guide on where to inject retatrutide
But it's also more expensive and can cause more side effects